Last reviewed · How we verify
Firmagon
At a glance
| Generic name | Firmagon |
|---|---|
| Also known as | Injection of Firmagon after a TEP-PSMA |
| Sponsor | Centre Leon Berard |
| Target | Gonadotropin-releasing hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced Prostatic Carcinoma
Common side effects
- Injection site pain
- Injection site erythema
- Hot flashes
- Increased serum transaminases
- Increased gamma-glutamyltransferase (GGT)
- Injection site swelling
- Injection site induration
- Injection site nodule
- Pyrexia
- Weight loss or gain
- Fatigue
- Anti-degarelix antibody development
Serious adverse events
- Grade 3/4 injection site reactions
- Grade 3 hepatic laboratory abnormalities
- Injection site infections including abscess
- Grade 3 hepatic transaminase elevations (extension study)
Key clinical trials
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (PHASE2)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Firmagon CI brief — competitive landscape report
- Firmagon updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI